| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $53.7M | — | +171.3% |
| SG&A Expense | $10.8M | — | +188.0% |
| Operating Income | -$64.5M | — | -174.0% |
| Net Income | -$60.7M | — | -171.6% |
| EPS (Basic) | -$1.34 | — | +95.4% |
| EPS (Diluted) | -$1.34 | — | +95.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $55.7M | +19.2% | — |
| Short-term Investments | $254.4M | -1.5% | — |
| Current Assets | $327.2M | +0.8% | — |
| Total Assets | $418.8M | -12.7% | — |
| Current Liabilities | $14.3M | -12.0% | — |
| Total Liabilities | $19.0M | -10.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$51.2M | — | -100.3% |
| Capital Expenditures | $24K | — | — |
| Investing Cash Flow | $67.0M | — | +78.7% |
| Financing Cash Flow | -$6.9M | — | — |
| Free Cash Flow | -$51.2M | — | — |
| — |
| Stockholders' Equity | $399.8M | -12.8% | +285.3% |